Sanofi has been a leader in vaccines for over 100 years.
The combination of our innovative vaccines and global reach means that many diseases do not hold the power they once did.
Our determination to improve public health motivates us to develop new vaccines to address still unmet medical needs. Fueled by new data and digital technologies, our science and manufacturing have the potential to transform the practice of medicine for millions of people around the world.

Sanofi Vaccines Profile 2023

Over half a billion people vaccinated annually with our vaccines worldwide

A world leader in influenza and pediatrics vaccines

10 new vaccines in clinical trials by 2025, including 6 using mRNA technologies

395 million supply of polio vaccines to UNICEF since 2014

World-class partnerships with major universities, research institutes, government bodies, international health organizations and patient associations

Aiming to save 330 tons of plastic per year and achieve carbon neutrality by 2030

€7.2 billion in sales in 2022

Our vaccines are available in about 150 countries
Our **Presence**

**Vaccines Industrial Sites**
- Canada: Toronto
- United States: Cambridge, Meriden, Orlando, Swiftwater, Pilar
- Mexico: Ocoyoacac
- Japan: Chachoengsao
- China: Shenzhen, Neveille-sur-Saône, Marcy-L’Étoile
- France: Val-de-Reuil, Neuville-sur-Saône
- United States: Pearl River, Pearl River
- India: Hyderabad
- Singapore: Republic of Singapore
- Argentina: Pilar
- France: Marcy-L’Étoile
- France: Neuville-sur-Saône
- France: Val-de-Reuil

**Vaccines R&D Sites**
- Canada: Toronto
- United States: Cambridge, Swiftwater, Meriden, Orlando, Pilar, Ocoyoacac
- Mexico: Ocoyoacac
- China: Shenzhen
- India: Hyderabad
- Singapore: Republic of Singapore
- Argentina: Pilar
- France: Val-de-Reuil
- France: Neuville-sur-Saône
- France: Marcy-L’Étoile
- France: Val-de-Reuil

---

**Industrial Sites**
- More than 2,500,000 doses of vaccines produced daily
- 12 sites
- More than 60% of our employees work in manufacturing and quality

**R&D Sites**
- >500,000 euros invested every year
- 5 main sites
- 9% of our employees

---

**EVolutive Facilities:**

Fully digitalized, our EVolutive Facilities (EVF) will enable more responsive and flexible manufacturing across multiple vaccine and biological platforms including mRNA, while minimizing our impact on the environment. Our EVFs will help improve people’s lives by giving them faster access to more vaccines and treatments.

---

**About Sanofi**

Our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. And to never settle. Fueled by data and digital technologies, our cutting-edge science and manufacturing have the potential to transform the practice of medicine, turning the impossible into possible for millions of people around the world. By chasing the miracles of science to improve people’s lives, we surprise ourselves with what we can achieve. And when we discover the extraordinary, we’re already planning where to go next.